Reuters logo
BRIEF-AC Immune partner Genentech to start second Phase 3 clinical trial for Alzheimer's therapy Crenezumab
February 28, 2017 / 10:10 AM / 7 months ago

BRIEF-AC Immune partner Genentech to start second Phase 3 clinical trial for Alzheimer's therapy Crenezumab

Feb 28 (Reuters) - Ac Immune Ltd

* Ac immune partner genentech to start second phase 3 clinical trial for alzheimer’s therapy crenezumab

* Ac immune will not receive any milestone payments for start of this second phase 3 trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below